TruSight Sequencing Panels

TruSight Sequencing Panels

For cost-effective, streamlined, targeted next-generation sequencing (NGS) of specific genetic diseases or conditions, Illumina offers TruSight sequencing panels. Designed with recognized healthcare experts at leading institutions, TruSight panels comprise oligo probes targeting genes and regions thought to be relevant for particular diseases or conditions.

Each TruSight sequencing panel offers:

  • Streamlined Workflow: Pre-designed, expert-selected content and use of proven Illumina NGS technology reduce assay optimization time and risk of manual error.
  • Accurate Results: Deep uniform coverage enables highly accurate variant calling suitable for the clinical research laboratory.
  • Increased Productivity: Product lot testing, extended shelf life, and single-lot shipments keep your lab running while reducing costs; TruSight One Sequencing Panel is able to replace multiple genetic assays.
TruSight Tumor 170

Comprehensive panel detects single-nucleotide variants (SNVs), amplifications, and fusions that contribute to solid tumor progression.

TruSight Oncology UMI Reagents

The TruSight Oncology UMI Reagents and UMI Error Correction App reduce error rates in samples to ≤0.007%, enabling the detection of low frequency variants.

TruSight RNA Fusion

Targeting 507 fusion associated genes in cancer; detects known and novel fusion gene partners.

TruSight One Sequencing Panels

Comprehensive panels targeting disease-associated regions of the exome with high analytical sensitivity and specificity.

TruSight HLA

Accurate, unambiguous, phase-resolved HLA typing in a single assay.

TruSight RNA Pan-Cancer

Targeting 1385 oncology genes for gene expression, variant and fusion detection in all RNA sample types including FFPE.

TruSight Myeloid

Uses expert-defined content to identify somatic mutations in myeloid malignancies.

TruSight Cancer

Targeting genes previously linked to a predisposition towards cancer.

TruSight Tumor 15

Focused panel assesses common somatic variants in solid tumors.

TruSight Cardio

Focusing on identifying inherited cardiac conditions.

TruSight Inherited Disease

Focusing on severe, recessive pediatric onset diseases.

AmpliSeq for Illumina Sequencing Solution

A highly multiplexed polymerase chain reaction (PCR)-based workflow for use with targets ranging from a few to hundreds of genes in a single run.

Cancer Research Panel Portfolio

Illumina offers a broad portfolio of cancer-focused products across multiple application areas.

TruSight Oncology 500

Assay targeting multiple variant types, including tumor mutational burden (TMB) and microsatellite instability (MSI), even from low-quality samples.

Discontinued TruSight products and recommended replacements are shown below: